Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, cross-over trial

Liraglutide: short-lived effect on gastric emptying-long lasting effects on body weight

(2012) J. Jelsing et al.   DIABETES OBESITY & METABOLISM

Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes

(2012) Michael Horowitz et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

The effect of vildagliptin therapy on atherogenic postprandial remnant particles and LDL particle size in subjects with Type 2 diabetes

(2012) N. Matikainen et al.   DIABETIC MEDICINE

Elevated Amylase and Lipase Levels in Patients Using Glucagonlike Peptide-1 Receptor Agonists or Dipeptidyl-Peptidase-4 Inhibitors in the Outpatient Setting

(2012) Howard Lando et al.   Endocrine Practice

The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients

(2011) Anne Flint et al.   ADVANCES IN THERAPY

The effect of the once-daily human glucagon-like peptide 1 analog liraglutide on the pharmacokinetics of acetaminophen

(2011) Christoph Kapitza et al.   ADVANCES IN THERAPY

Effects of Nutrients on Postprandial Lipemia

(2011) Denis Lairon et al.   Current Vascular Pharmacology

Methods to Study Postprandial Lipemia

(2011) Teik Chye Ooi et al.   Current Vascular Pharmacology

Rapid Tachyphylaxis of the Glucagon-Like Peptide 1-Induced Deceleration of Gastric Emptying in Humans

(2011) M. A. Nauck et al.   DIABETES

Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2—3 liraglutide clinical development studies

(2011) Steven P Marso et al.   Diabetes & Vascular Disease Research

Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes

(2011) A. J. Tremblay et al.   DIABETES OBESITY & METABOLISM

Newly appreciated therapeutic effect of GLP-1 receptor agonists: Reduction in postprandial lipemia

(2010) Robert H.J. Bandsma et al.   ATHEROSCLEROSIS

Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus

(2010) Eric A. Schwartz et al.   ATHEROSCLEROSIS

One-year treatment with exenatide vs. Insulin Glargine: Effects on postprandial glycemia, lipid profiles, and oxidative stress

(2010) Mathijs C. Bunck et al.   ATHEROSCLEROSIS

Postprandial lipaemia, oxidative stress and endothelial function: a review

(2010) J. P. Wallace et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Differential effects of protein quality on postprandial lipemia in response to a fat-rich meal in type 2 diabetes: comparison of whey, casein, gluten, and cod protein

(2009) Lene S Mortensen et al.   AMERICAN JOURNAL OF CLINICAL NUTRITION

Liraglutide: A Once-Daily Incretin Mimetic for the Treatment of Type 2 Diabetes Mellitus

(2009) Joshua J Neumiller et al.   ANNALS OF PHARMACOTHERAPY

The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1-5 studies

(2009) L. Blonde et al.   DIABETES OBESITY & METABOLISM

The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice

(2009) J. Hsieh et al.   DIABETOLOGIA

Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study

(2008) Ralph A. DeFronzo et al.   CURRENT MEDICAL RESEARCH AND OPINION

The Effects of Medications Used for the Management of Dyslipidemia on Postprandial Lipemia

(2008) N. Tentolouris et al.   CURRENT MEDICINAL CHEMISTRY

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

(2008) Alan Garber et al.   LANCET